Evidence map›Paper›PMID 35125334›Full record

ArticleJournal of geriatric oncology2022

Decision-making about clinical trial options among older patients with metastatic cancer who have exhausted standard therapies.

Mazie Tsang, Rebecca J DeBoer, Sarah B Garrett, Daniel Dohan

Open access · hybridAbstract read
In one paragraph

Article in Journal of geriatric oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mazie TsangDivision of Hematology/Oncology, University of California San Francisco, 505 Parnassus Avenue, Room M1286, Mailbox 1270, San Francisco, CA 94143, United States. Electronic address: Mazie.Tsang@ucsf.edu.
Rebecca J DeBoerDivision of Hematology/Oncology, University of California San Francisco, 505 Parnassus Avenue, Room M1286, Mailbox 1270, San Francisco, CA 94143, United States. Electronic address: Rebecca.DeBoer@ucsf.edu.
Sarah B GarrettInstitute for Health Policy Studies, University of California San Francisco, 490 Illinois Street, San Francisco, CA 94158, United States. Electronic address: Sarah.Garrett@ucsf.edu.
Daniel DohanInstitute for Health Policy Studies, University of California San Francisco, 490 Illinois Street, San Francisco, CA 94158, United States. Electronic address: Daniel.Dohan@ucsf.edu.
University of California, San Francisco · US

Funding

RESEARCH TRAINING IN GERIATRIC MEDICINET32AG000212 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alexander Keliimoeanu Smith · 1991 to 2026
$7.7M
UC Berkeley-UCSF Health Services Research Training ProgramT32HS022241 · AHRQ · UNIVERSITY OF CALIFORNIA BERKELEY · PI RODRIGUEZ, HECTOR P. · 2013 to 2024
$3.2M
Before Consent: Cancer Patients' Deliberations about Early Phase Clinical TrialsR01CA152195 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DOHAN, DANIEL P. · 2010 to 2014
$2.6M
Leadership to Enhance Aging Research and Innovation in Medical Culture (LEARN-MC)K07AG066814 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DOHAN, DANIEL P. · 2020 to 2024
$675k
AHRQ HHS T32 HS022241NCI NIH HHS R01 CA152195NIA NIH HHS K07 AG066814NIA NIH HHS T32 AG000212
6 · The paper itself

Abstract

objectivesOlder adults under-enroll in early phase cancer clinical trials. There are limited data on their trial experiences, which hampers our ability to understand potential reasons and responses to under-enrollment. We aimed to explore older adults' experiences and deliberations with phase 1 trials. MATERIALS AND

methodsWe analyzed 101 in-depth interviews with 39 adults (average 2.6 interviews per participant) about their experiences with phase 1 trials. All respondents were ≥ 65 years and had advanced cancer. Interviews lasted 60-90 min and were audio-recorded, transcribed, and analyzed to identify respondents' understanding of clinical research, perceptions of early phase trials, and experiences with enrollment.

resultsClinical trial participation was an interactive process that unfolded over time. Older adults relied on ongoing guidance and discussion with their oncologist to navigate the process. Respondents were generally interested in life-prolonging therapies, including enrollment in early phase clinical trials, but did not necessarily state this explicitly to their oncologist. While respondents did not mention age as a limitation to trials participation, participants age > 70 were less enthusiastic about participation and more often discussed their quality of life and weighed benefits of trial participation in the context of their remaining months of life.

conclusionEarly phase clinical trial enrollment is complex, and older adults rely on their oncologist to navigate this process. Acknowledging this complexity through shared decision-making may ensure that older adults have appropriate opportunities to enroll in early phase clinical trials and guard against inappropriate under-enrollment.

Indexed as

NeoplasmsQuality of LifeAgedClinical Trials as TopicHumansPatient SelectionStandard of CareAdvanced cancerClinical trial enrollmentDecision-makingGeriatric oncologyOlder adultsPatient deliberationPhase 1 trials

Identifiers

PMID35125334
PMCPMC9232893
OpenAlexW4210671355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.